GLP-1 and GLP-2 therapies have also been associated with improvements in intestinal epithelial barrier function, reducing local inflammation, which may be beneficial to resolving NASH (3, 7, 36). Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.